Royalty Report: Drugs, Biotechnology, Agriculture Forestry & Fishing – Collection: 7288

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Biotechnology
  • Agriculture Forestry & Fishing
  • Crop Production
  • Vaccine
  • Proteins
  • Antibody

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 7288

License Grant
Licensor hereby grants to Swiss Licensee an exclusive license, with the right to grant sublicenses, under the Licensor Technology and Licensor's interest in the Project Technology to make, have made, use, import, offer for sale and sell Products.
License Property
Technology shall mean Licensor's proprietary packaging cell lines, high-speed functional genomic screening technology, two-hybrid screening assays, retroviral vector systems and expression systems that utilize these vectors to express libraries of molecules in target cells and high speed fluorescent cell sorting systems and any improvements thereon, and any Patents and Know-How relating thereto owned or Controlled by Licensor, subject to any limitation contained in the agreements under which Licensor's rights to the use of such Licensor Core Technology are derived.

IPSCIO Record ID: 56588

License Grant
In this related party agreement, the Licensor hereby grants to Licensee a nonexclusive license in the Territory, with the right to sublicense, to use iBioLaunchâ„¢ Technology and iBio Additional Technology to conduct Process Development, Scale-Up, and R&D activities on Pharmaceutical Products in the Territory. Additionally, subject to the terms and conditions of this Agreement, Licensor hereby grants to Licensee a nonexclusive license in the Territory, with the right to sublicense, to use the iBio Additional Technology to conduct Process Development, Scale-Up, and R&D activities on Products in the Territory.
License Property
The patents and technology are for the accelerated discovery and production of improved vaccines, monoclonal antibodies, therapeutic proteins, and other products derived from green plants utilizing its iBioLaunchâ„¢ plant-based platform technology and other proprietary technologies.

7,012,172   VIRUS INDUCED GENE SILENCING IN PLANTS   3/14/2006
          
7,491,509   SYSTEM FOR EXPRESSION OF GENES IN PLANTS   2/17/2009
          
7,683,238   PRODUCTION OF PHARMACEUTICALLY ACTIVE PROTEINS IN SPROUTED SEEDLINGS   3/23/2010
          
7,692,063   PRODUCTION OF FOREIGN NUCLEIC ACIDS AND POLYPEPTIDES IN SPROUT SYSTEMS   4/6/2010
          
8,058,511   SYSTEM FOR EXPRESSION OF GENES IN PLANTS   11/15/2011
          
8,148,608   SYSTEMS AND METHODS FOR CLONAL EXPRESSION IN PLANTS   4/3/2012
          
8,173,408   RECOMBINANT CARRIER MOLECULE FOR EXPRESSION, DELIVERY AND PURIFICATION OF TARGET POLYPEPTIDES   5/8/2012
          
8,591,909   RECOMBINANT CARRIER MOLECULE FOR EXPRESSION, DELIVERY AND PURIFICATION OF TARGET POLYPEPTIDES   11/26/2013
          
8,597,942   SYSTEM FOR EXPRESSION OF GENES IN PLANTS   12/3/2013
          
8,951,791   SYSTEM FOR EXPRESSION OF GENES IN PLANTS   2/10/2015
          
9,012,199   RECOMBINANT CARRIER MOLECULE FOR EXPRESSION, DELIVERY AND PURIFICATION OF TARGET POLYPEPTIDES   4/21/2015

Field of Use
This agreement pertains to the patents and technologies for research, process development and scale-up, and manufacturing of plant-derived products in a manufacturing facility designed for that purpose relating to drugs in the healthcare industry.

IPSCIO Record ID: 26111

License Grant
Library Technology. Licensor hereby grants to Licensee a worldwide, non-exclusive right and license (without any right to grant sublicenses except to Sublicensed Recipients under the terms and under Licensor's rights in the Library Technology, including, without limitation, any Patent Rights Controlled by Licensor Covering the foregoing, (a) to use the OmniBank II Library and Mutant Mice obtained from the Existing OmniBank Library and (b) to make, use and sell Materials derived therefrom. Licensee's right under the foregoing license to sell Materials shall be subject to Cre-Lox Patents.
License Property
Licensor has technology for and expertise in the generation of mouse embryonic stem cell clones containing gene trap mutations that can be used in the production of knockout mice.

Licensor and Licensee are interested in collaborating in the start-up and initial operations of TIGM, including the endowment of TIGM with a library of such mouse embryonic stem cell clones containing gene trap mutations.

'Bioinformatics Software' means the software for the management and analysis of data relating to the OmniBank II Library and the production, genotyping and phenotypic analysis of knockout mice.

The Bioinformatics Software is an online analytical and decision-support system that catalogs the in vivo characterization of all mouse embryonic stem cell clones contained in the OmniBank II Library. Users can assess and search a wide range of phenotypic information at different levels, including raw data, calculated graphs with annotated summaries, and statistical analysis for selected diagnostic areas, by means of a standard web browser. Information can be retrieved through an intuitive search interface by gene description and sequence, disease indication, keywords, related publications and statistical significance.

'Materials' means Mutant Mice, Progeny and cells, tissues and other biological materials derived from any of the foregoing; provided that Materials shall not include cells, tissues or other biological materials that do not contain a Selected Mutation.

'Progeny' means mice, including successive generations thereof, that are produced, developed or derived by or on behalf of TIGM or Sublicensed Recipients directly or indirectly from a Mutant Mouse progenitor.

CRE-LOX PATENTS:
4,959,317

GENE TRAPPING PATENTS:
USA                                6,136,566     10/24/00      10/4/2016
USA                                6,207,371     3/27/01       10/4/2016
PCT        PCT/US98/16373
USA                                6,139,833     10/31/00      8/8/2017
PCT        PCT/US99/06474
USA                                6,080,576     6/27/00       4/8/2018
PCT        PCT/US99/27366
USA                                6,436,707     8/20/02       4/8/2018
USA                                6,776,988     8/17/04       7/26/2019
USA                                6,218,123     4/17/01       8/10/2019
USA                                6,855,545     2/15/05       2/27/2017
USA                                6,808,921     10/26/04      4/18/2018

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.